Adults presenting with sporadic hypophosphatemia and elevations in circulating fibroblast growth 4 factor-23 (FGF23) concentrations are usually investigated for an acquired disorder of FGF23 excess 5 such as tumor induced osteomalacia (TIO). However, in some cases the underlying tumor is not 6 detected, and such patients may harbor other causes of FGF23 excess. Indeed, coding-region and 7 3'UTR mutations of phosphate-regulating neutral endopeptidase (PHEX), which encodes a cell-8 surface protein that regulates circulating FGF23 concentrations, can lead to alterations in phosphate 9 homeostasis, which are not detected until adulthood. Here, we report an adult female who presented 10 with hypophosphatemic osteomalacia and raised serum FGF23 concentrations. The patient and her 11 parents, who were her only first-degree relatives, had no history of rickets. The patient was thus 12 suspected of having TIO. However, no tumor had been identified following extensive localization 13 studies. Mutational analysis of the PHEX coding-region and 3'UTR was undertaken, and this revealed 14 the patient to be heterozygous for a novel germline PHEX mutation (c.2158G>T; p.Ala720Ser). In 15 vitro studies involving the expression of WT and mutant PHEX proteins in HEK293 cells 16 demonstrated the Ala720Ser mutation to impair trafficking of PHEX, with <20% of the mutant 17 protein being expressed at the cell surface, compared to >80% cell surface expression for WT PHEX 18 (p<0.05). Thus, our studies have identified a pathogenic PHEX mutation in a sporadic case of adult-19 onset hypophosphatemic osteomalacia, and these findings highlight a role for PHEX gene analysis in 20 some cases of suspected TIO, particularly when no tumor has been identified. 21 22 23 24 Abbreviations: ALP, alkaline phosphatase; ESR, erythrocyte sedimentation rate; EVS, Exome 25 Variant Server; EXAC, Exome Aggregation Consortium; FDG, 18 fluorodeoxyglucose; FGF23, 26 fibroblast growth factor-23; PHEX, phosphate-regulating neutral endopeptidase; PsA, psoriatic 27 arthritis; TIO, tumor induced osteomalacia; TmP/GFR, Tubular maximum of phosphate/glomerular 1. Introduction 1 2
1 hypophosphatemia. She had no childhood history of rickets, and the onset of her hypophosphatemia 2 was not known, as serum biochemical profiling had not been previously undertaken. Moreover, it was 3 uncertain whether there was a family history of rickets as she had no children or siblings. However, 4 her parents were not known to be of short stature or affected by any musculoskeletal disorders. She 5 had a history of dental abscesses, which were attributed to dental trauma as a child. Her height was 6 150 cm (4 feet and 11 inches), which is within the normal range for women of her ethnicity (Middle 7 Eastern origin) and corresponds to the 12 th height centile. No disproportionate lower limb shortening 8 was noted, and the upper and lower segment heights were 70cm and 80cm, respectively. No frontal 9 bossing or other skeletal deformities were detected on examination. Mild enthesopathic changes 10 affecting the ischial tuberosities, and an incidental finding of L5 spina bifida, were noted on a review 11 of her plain radiographs ( Fig. 1A Our studies have identified a pathogenic PHEX mutation in a patient with elevated circulating FGF23
16
concentrations and hypophosphatemic osteomalacia that first manifested in adulthood. Although,
17
PHEX mutations are occasionally detected in osteomalacic adults (24), and even in asymptomatic 18 adults (25), such cases usually arise within a kindred known to be affected with XLH. In contrast, the 19 patient reported here did not have a known family history of rickets or osteomalacia, which indicates 20 that her adult-onset XLH had likely occurred sporadically. It is of note that this patient was also showing the co-localisation of PHEX (red) with calnexin, which is an ER-associated protein (green). 
